

Pfizer Research Grant Request for Proposals

Competitive Grant Program – Pfizer Internal Review Process

Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease Registry



Overview

This competitive research grant program seeks to advance real-world evidence generation in idiopathic inflammatory myopathies (IIM) through German disease registry initiatives. The program welcomes applications from existing or developing registries as well as institutions seeking to build the infrastructure needed to collect longitudinal, high-quality data on disease burden, care pathways, treatment patterns, outcomes, safety, and unmet needs, including data structures that enable feasible regulatory safety reporting where applicable. The resulting evidence should strengthen the understanding of IIM in Germany and support future improvements in patient care.



Geographic Scope

Germany



Project Types and Area of Interest

Potential applicants are encouraged to apply for projects, that:

- *Support the establishment or expansion of German registry initiatives in idiopathic inflammatory myopathies (IIM), including existing, developing, or newly planned registries.*
- *Enable longitudinal real-world data collection on disease burden, care pathways, treatment patterns, outcomes, safety, and unmet needs in Germany.*
- *Support data structures and processes that allow feasible regulatory safety reporting where applicable.*



Key Milestones



Funding Range and Project Length

Individual projects requesting funding up to 3 years and a max. amount of up to 350,000 € will be considered.

I. Eligibility

Geographic Scope:

- Germany

Applicant Eligibility Criteria

- The institution and Principal Investigator (PI) must be based Germany.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical degree and be an employee or contractor of the requesting organization.
- Requesting organizations must be legally able to receive award funding directly from Pfizer LLC.

II. Requirements

Primary Area of Interest:

- Inflammation & Immunology; idiopathic inflammatory myopathies (IIM)

General Area of Interest for this RFP:

- Projects that will be considered for Pfizer support should focus on establishing or strengthening the infrastructure required for a German disease registry in IIM.
- Projects should describe a longitudinal registry infrastructure capable of capturing standardized physician-reported and patient-reported data.
- Data collection is expected to align, where feasible, with the consensus-based myositis Common Data Elements (CDE) described by Saygin et al. (Arthritis Care & Research, 2026; doi:10.1002/acr.80032).
- Proposals should explain how the proposed core dataset maps to these CDEs and supports interoperability with national and international myositis registries and research initiatives.
- The registry should aim to include patients managed across the relevant specialties involved in IIM care, including rheumatology, dermatology, and neurology, and across hospital-based, specialist-center and office-based care settings, to improve representativeness of the German care pathway.
- Proposals should also describe follow-up schedules, data quality measures, site training, governance, and structured processes for adverse event documentation to enable feasible regulatory-level safety reporting where applicable.
- Applicants should provide a clear and realistic milestone-based implementation plan for the full proposed project period.

- The plan should describe how the registry will become operational and initiate patient recruitment no later than early 2028, followed by an initial period of multicentre recruitment, longitudinal follow-up, data-quality management and preparation for sustainable operation.
- Applicants should define the objectives, activities, deliverables and proposed budget for each project phase. The phasing should reflect the applicant's independent scientific and operational plan and may include:
 - Establishment of governance, protocol, ethics and data-protection processes; development of the core dataset and data infrastructure; initiation and continuation of patient recruitment; longitudinal follow-up and data-quality monitoring; development of initial scientific outputs; and preparation for sustainable operation beyond the funded project period.
- Applicants should demonstrate a strong track record and relevant experience in the setup, governance, and conduct of clinical registry projects, preferably in rheumatology and/or related immune-mediated inflammatory diseases.
- Projects must be investigator-led and independent; Pfizer must not be involved in protocol development, registry conduct, data analysis, or publication decisions.

Expected Approximate Monetary Range of Grant Applications

IMPORTANT: Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- Funding may be used to support project-related costs required to establish or strengthen registry infrastructure, including personnel time, project management, data management, statistical or methodological support, ethics/regulatory submissions, site setup, and registry operational activities. **Individual projects requesting up to 350,000€** will be considered. The **estimated total available budget related to this RFP is 350,000 €**.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Click here to navigate to this Competitive Grant Program's unique Program Application Form: [Login](#)
 - First-time users should create a Requester Portal account by clicking **Not a member?**
- OR
- Navigate to: <https://pfizermarcie.my.site.com/pfzrequester> and sign in.
- In the upper navigation bar, click **Grant Programs** to see all available programs.
- Select **Research**
- Click **Apply** on the “**2026 RFP German Inflammatory Myopathy Registry**” to open the Program Application Form.
- Requirements for submission:
 - Complete all required sections of the online application
 - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
 - For more information on navigating Pfizer's new grant management system (MARCIE), please refer to this helpful [User Guide](#).

Questions:

- Please click [here](#) to view “Frequently Asked Questions” regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to Global Medical Grants mailbox (GlobalMedicalGrants@pfizer.com), with the subject line “**2026 RFP German Inflammatory Myopathy Registry**”

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
- Proposals will be evaluated based on alignment with the RFP objectives, feasibility of registry setup and recruitment readiness by early 2028, applicant registry experience, and ability to support regulatory-level safety reporting where applicable.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.

- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Proposals should be single-spaced, use 12-point font and 1-inch margins, and should not exceed 10-15 pages. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Describe the main goal of the project, with emphasis on establishing, expanding, or strengthening the infrastructure required for a German IIM registry. Clearly state how the project will enable the registry to become operational and initiate patient recruitment no later than early 2028.

Target Audience & Beneficiaries

- Describe the intended registry population, including relevant IIM subtypes, participating sites, and expected patient population. Explain how the participating network will ensure representation across IIM subtypes, relevant specialties, geographic regions, and hospital-based versus office-based care. Indicate who will benefit from the registry outputs, including patients, clinicians, researchers, and other healthcare stakeholders.

Project Design and Methods

- Describe the planned longitudinal registry design and infrastructure, including governance, operational model, participating sites, site activation approach, baseline and follow-up assessments, physician-reported and patient-reported data capture, core data elements, data quality measures, consent approach, data protection concept, and ethics/regulatory approval pathway. Provide a proposed core dataset and indicate how the collected variables map to published myositis Common Data Elements (CDEs), including physician-reported outcomes, patient-reported outcomes, disease activity measures, damage assessments, autoantibody status, treatment exposure, and safety outcomes.

Regulatory Safety Reporting Feasibility

- Describe how the registry infrastructure, data elements, workflows, and responsibilities will support feasible regulatory-level safety reporting where applicable.

Evaluation and Outcomes

- Describe how project progress and registry readiness will be assessed, including key milestones such as governance setup, protocol finalization, site readiness, data system readiness, and recruitment initiation. Include any planned scientific outputs or dissemination activities.

Anticipated Project Timeline

- Provide a milestone-based timeline, including project start/end dates and the planned steps required to ensure recruitment can begin no later than early 2028.
- Applicants should indicate, for each project phase and associated milestone, the timing and amount of funding required. The proposed payment schedule should be aligned with the planned activities and deliverables.
 - Please note that each individual payment may not exceed €100,000.
 - Funding in the first year is limited to 100,000€.
 - The overall maximum grant amount is €350,000.

Additional Information

- Summarize any additional information relevant to the importance, feasibility, sustainability, or expected impact of the proposed registry infrastructure project.

Organization Detail

- Describe the applicant organization's relevant experience, resources, and capabilities, including prior experience in registry setup, governance, and conduct, preferably in rheumatology and/or immune-mediated inflammatory diseases.

Budget Detail

- The budget amount requested must be in Euro (€).
- While estimating your budget please keep the following items in mind:
- General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
- The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
- Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.